Jonas Karl Hansson
Président chez Tribune Therapeutics AB
Profil
Jonas Karl Hansson is currently the Executive Chairman at Tribune Therapeutics AB, Director at FE Fonder AB, Partner at Healthcap VI GP SA, Partner at HealthCap Advisor AB, and Partner at HealthCap VII GP SA. He previously served as the Chief Executive Officer at Wilson Therapeutics AB from 2012 to 2018.
He was also a Director at Revent Medical, Inc. and Prothelia, Inc. Additionally, he worked as a Key Account Manager at Janssen Pharma AB.
Mr. Hansson holds an MBA from Stockholm School of Economics and a graduate degree from the University of Uppsala.
Postes actifs de Jonas Karl Hansson
| Sociétés | Poste | Début |
|---|---|---|
| Healthcap VI GP SA | Corporate Officer/Principal | - |
| HealthCap VII GP SA | Corporate Officer/Principal | - |
HealthCap Advisor AB
 HealthCap Advisor AB Investment ManagersFinance HealthCap Advisor AB provides investment advice. The private company is based in Stockholm, Sweden. | Corporate Officer/Principal | 01/01/2019 |
Tribune Therapeutics AB
 Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | Président | - |
FE Fonder AB
 FE Fonder AB Investment ManagersFinance FE Fonder AB is a private company based in Stockholm, Sweden. The Swedish company's expertise lies in the field of fund management, making them an ideal external resource for market and distribution. | Directeur/Membre du Conseil | - |
Anciens postes connus de Jonas Karl Hansson
| Sociétés | Poste | Fin |
|---|---|---|
HealthCap AB
 HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Analyste en capital-investissement | 01/06/2012 |
| SPRUCE BIOSCIENCES, INC. | Directeur/Membre du Conseil | 20/05/2021 |
| WILSON THERAPEUTICS AB | Directeur Général | 01/06/2018 |
| Janssen Pharma AB | Corporate Officer/Principal | - |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Jonas Karl Hansson
| Stockholm School of Economics | Masters Business Admin |
| University of Uppsala | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SPRUCE BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
HealthCap AB
HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Finance |
Revent Medical, Inc.
 Revent Medical, Inc. Pharmaceuticals: MajorHealth Technology Revent Medical, Inc. develops cost effective and innovative medical implants for patients with obstructive sleep apnea. The company was founded by Edward M. Gillis in 2008 and is headquartered in Newark, CA. | Health Technology |
Wilson Therapeutics AB
 Wilson Therapeutics AB Pharmaceuticals: MajorHealth Technology Wilson Therapeutics AB engages in the development of novel therapies for patients with rare copper-mediated disorders. The company was founded on April 25, 2012 and is headquartered in Stockholm, Sweden. | Health Technology |
| Healthcap VI GP SA | |
| HealthCap VII GP SA | |
HealthCap Advisor AB
HealthCap Advisor AB Investment ManagersFinance HealthCap Advisor AB provides investment advice. The private company is based in Stockholm, Sweden. | Finance |
Prothelia, Inc.
 Prothelia, Inc. BiotechnologyHealth Technology Prothelia, Inc. operates as a biotechnological company that engages in the provision of protein therapy. It focuses on the treatment of congenital muscular dystrophy type 1A. The company was founded by Bradley Hodges and is headquartered in Milford, MA. | Health Technology |
Tribune Therapeutics AB
Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | Commercial Services |
FE Fonder AB
FE Fonder AB Investment ManagersFinance FE Fonder AB is a private company based in Stockholm, Sweden. The Swedish company's expertise lies in the field of fund management, making them an ideal external resource for market and distribution. | Finance |
| Janssen Pharma AB |
